Literature DB >> 11280738

Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

S M Ellerbroek1, J M Halbleib, M Benavidez, J K Warmka, E V Wattenberg, M S Stack, L G Hudson.   

Abstract

Activation of the epidermal growth factor (EGF) receptor regulates many processes associated with metastasis, including modulation of cell:cell and cell:substrate interactions, production of matrix-degrading proteinases, and cellular migration. We have demonstrated previously that EGF stimulates migration and matrix metalloproteinase (MMP)-9-dependent invasion of ovarian cancer cells. In this study, we compare the roles of EGF-induced phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) activities in regulation of cellular responses associated with ovarian tumor cell metastasis. Inhibition of PI3K and MAPK activity impairs EGF-stimulated cell migration, in vitro invasion, and MMP-9 production. PI3K activity is not required for growth factor disruption of cell:cell junctions, whereas inhibitors of extracellular signal-regulated kinase (ERK)1/ERK2 activation and p38 MAPK activity block EGF-dependent junction dissolution. EGF promotes pro-MMP-9 binding to the cell surface through a mechanism that is independent of extracellular enzyme concentration. Interestingly, inhibition of PI3K activity abolishes EGF-induced cell surface association of pro-MMP-9, whereas inhibitors of MAPKs only partially block the response. These data suggest that EGF receptor activation promotes a PI3K-dependent induction of a cell surface pro-MMP-9 binding component that may facilitate gelatinase-mediated cellular invasion and supports an expanded role for elevated PI3K activity in cellular responses associated with ovarian tumor metastasis. In addition, our findings support the hypothesis that divergent kinase activities regulate distinct cellular events associated with growth factor-induced invasion of ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280738

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

Review 2.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Matrix Biol       Date:  2015-04-22       Impact factor: 11.583

3.  2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol reverses EGF-induced cell migration and invasion through down-regulation of MDM2 in breast cancer cell lines.

Authors:  Dayong Zheng; Xing Chang; Yang Liu; Jingwen Xu; Wenfeng Gou; Zengqiang Li; Daiying Zuo; Weige Zhang; Yingliang Wu
Journal:  Cancer Biol Ther       Date:  2018-12-04       Impact factor: 4.742

4.  The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.

Authors:  Karen D Cowden Dahl; Richard Dahl; Jessica N Kruichak; Laurie G Hudson
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

5.  Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.

Authors:  Brandi R Whitley; Lea M Beaulieu; Jennifer C Carter; Frank C Church
Journal:  Gynecol Oncol       Date:  2006-10-30       Impact factor: 5.482

6.  PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

Authors:  Karen D Cowden Dahl; Reema Zeineldin; Laurie G Hudson
Journal:  Mol Cancer Res       Date:  2007-05-02       Impact factor: 5.852

7.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Mmp-9, a potential target for cerebral ischemic treatment.

Authors:  Xue Dong; Yu-Ning Song; Wei-Guo Liu; Xiu-Li Guo
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 9.  Promising new molecular targeted therapies in head and neck cancer.

Authors:  Kelly Dorsey; Mark Agulnik
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

10.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.